Apollomics, Inc. (NASDAQ:APLM) Sees Large Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 3,700 shares, a drop of 28.8% from the January 15th total of 5,200 shares. Based on an average daily trading volume, of 310,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.5% of the shares of the company are short sold.

Hedge Funds Weigh In On Apollomics

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC lifted its stake in shares of Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Price Performance

Shares of Apollomics stock traded down $0.04 during mid-day trading on Friday, hitting $6.73. 3,987 shares of the stock were exchanged, compared to its average volume of 9,245. Apollomics has a 12 month low of $6.38 and a 12 month high of $80.50. The company has a 50-day simple moving average of $9.18 and a 200 day simple moving average of $11.87.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.